Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Erdafitinib
Brand Name Balversa™
Payment Category Medicare Part D
Year Introduced 2019
Type of Drug Kinase inhibitor
Manufacturer Janssen Biotech
Medical Affairs Questions (date verified) 800.526.7736
Coverage & Reimbursement Questions 866.378.1910

FDA-Approved Indication(s)

  • Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have FGFR3 or FGFR2 genetic alterations and have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Balversa. (4/12/19)

Approved Indication(s) with Orphan Drug Status None
ICD-10 Code(s) for Labeled Indication(s) Malignant neoplasm of ureter [C66.x]; Malignant neoplasm of bladder [C67.x]; Malignant neoplasm of other and unspecified urinary organs [C68.x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949